Rapport Therapeutics, Inc. Common Stock (RAPP) Stock Price
RAPPStock
$51.17+233.99%52W
Market Cap$2.46B
P/E—
PEG Ratio—
Div yield—
Beta2.47
RAPP Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)57.69%
Price vs S&P 500 (4W)14.51%
VGM Score82.07
RAPP Earnings Surprise History
Q2 25-0.75est. -0.77
Q3 25-0.71est. -0.73
Q4 25-0.72est. -0.67
Q1 26-0.42est. -0.71
Q2 26-1.19est. -0.99
RAPP Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.29
4.29
4.33
4.37
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RAPPRapport Therapeutics, Inc. Common Stock | — | — | A | $51.17 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics is a clinical-stage biotechnology company developing small-molecule precision medicines for neurological and psychiatric disorders. Its lead program, RAP-219, is in clinical development for focal onset seizures, generalized tonic-clonic seizures, and bipolar mania. The company also maintains two discovery-stage nicotinic acetylcholine receptor programs targeting chronic pain and hearing disorders.